(Family Features) Thanks to a provision in the Patient Protection and Affordable Care Act, efforts are underway to streamline licensing for medications known as “biosimilars,” which are similar – but not identical – to cutting-edge biologic medicines. However, the development has some concerned about patient safety, especially among older Americans who tend to suffer from more chronic diseases, such as cancer, diabetes, and heart disease.
